PRTC PureTech Health plc
107.60GBp-0.19%Mkt Cap: 284.69M $P/E: —Today
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential…
Industry Peers
Biotechnology$127.85BUSDP/E 29.4
$75.86BUSD
$75.69BUSDP/E 18.2
$57.51BUSDP/E 35.1
$55.45BUSDP/E 35.2
$44.29BUSD
$42.34BUSDP/E 18.1
$40.51BUSDP/E 63.9
$33.03BUSDP/E 30.7
$29.40BUSDP/E 38.3
$25.80BUSD
$24.34BUSD
$24.27BUSD
$23.37BUSDP/E 14.7
$21.69BUSDP/E 27.4
$20.52BUSDP/E 27.1
$15.30BUSDP/E 16.1
$14.99BUSDP/E 17.8
$14.47BUSDP/E 18.4
$13.37BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ... PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year. | ||
 PureTech Health H1 Earnings Call Highlights PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entit | ||
AAskTraders | ||
SStock Traders Daily | ||